Table 1 Baseline Characteristics of patients treated with catheter ablation for atrial fibrillation
From: Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer
Cancer (n = 251) | No Cancer (n = 251) | P value | |
|---|---|---|---|
Age in years, median (IQR) | 67 (61–73) | 64 (56–70) | < 0.001 |
Female | 118 (47) | 107 (42.6) | 0.32 |
Height in meters, median (IQR) | 1.73 (1.65–1.80) | 1.73 (1.65–1.80) | 0.83 |
Weight in kg, median (IQR) | 86.18 (76.10–99.75) | 91.4 (76.34–109.35) | 0.01 |
BMI in kg/m2, median (IQR) | 29 (25–33) | 30.19 (26.17–35.25) | 0.70 |
Comorbidities | |||
Hypertension | 166 (66.1) | 168 (66.9) | 0.85 |
Hyperlipidemia | 143 (57) | 112 (44.6) | 0.006 |
Diabetes | 38 (15.1) | 51 (20.3) | 0.13 |
HbA1c %, median (IQR) | 5.6 (5.3–6.2) | 5.7 (5.3–6.1) | 0.86 |
Obstructive sleep apnea | 63 (25.1) | 53 (21.1) | 0.35 |
Smoker | 0.63 | ||
Former | 98 (39) | 108 (43) | |
Current | 17 (6.8) | 14 (5.6) | |
Coronary artery disease | 41 (16.3) | 36 (14.3) | 0.54 |
Heart failure | 0.50 | ||
Reduced ejection fraction | 44 (17.5) | 52 (20.7) | |
Preserved ejection fraction | 21 (8.4) | 16 (6.4) | |
NYHA classification | 0.23 | ||
NYHA 1 | 136 (54.2) | 139 (55.4) | |
NYHA 2 | 78 (31.1) | 89 (35.4) | |
NYHA 3 | 25 (10) | 14 (5.6) | |
NYHA 4 | 4 (1.6) | 1 (0.4) | |
Prior Stroke/TIA | 20 (8) | 14 (5.6) | 0.29 |
Atrial Fibrillation (AF) Variables | |||
Type of AF | 0.83 | ||
Paroxysmal | 136 (54.2) | 141 (56.2) | |
Persistent | 105 (41.8) | 103 (41) | |
Long standing persistent | 9 (3.6) | 7 (2.8) | |
Prior cardioversion for AF | 151 (60.2) | 145 (57.8) | 0.59 |
CHA2DS2-VASc score, median (IQR) | 2(1–4) | 2(1–3) | 0.06 |
Drugs used to manage AF before ablation | |||
Amiodarone | 77 (30.7) | 40 (15.9) | < 0.001 |
Dronedarone | 19 (7.6) | 12 (4.8) | 0.19 |
Flecainide | 74 (29.5) | 57 (22.7) | 0.08 |
Dofetilide | 43 (17.1) | 31 (12.3) | 0.13 |
Propafenone | 18 (7.2) | 12 (4.8) | 0.35 |
Sotalol | 78 (31.2) | 68 (27.1) | 0.32 |
Verapamil/Diltiazem | 62 (24.7) | 54 (21.5) | 0.50 |
Beta Blockers | 187 (74.5) | 177 (70.5) | 0.32 |
Digoxin | 26 (10.4) | 22 (8.8) | 0.46 |
Warfarin | 105 (41.8) | 69 (27.5) | 0.002 |
Direct Oral Anticoagulants | 141 (56.2) | 146 (58.2) | 0.33 |
Procedural characteristics | |||
Type of ablation | < 0.001 | ||
Pulmonary vein isolation | 114 (45.4) | 154 (61.4) | |
Pulmonary vein isolation plus lines | 137 (54.6) | 97 (38.6) | |
Modality of ablation | < 0.001 | ||
Radiofrequency ablation | 146 (58.2) | 21 (8.4) | |
Cryoablation | 91 (36.2) | 134 (53.4) | |
Both | 14 (5.6) | 96 (38.3) | |
Cancer patient specific variables | |||
Type of cancer | |||
Breast carcinoma | 75 (29.9) | ||
Lung carcinoma | 15 (6.0) | ||
Prostate carcinoma | 56 (22.3) | ||
Lymphoma | 25 (10.0) | ||
Other cancer | 80 (31.9) | ||
Metastatic disease | 28 (11.2) | ||
Active treatment at the time of ablation | 46 (18.3) | ||
Systemic chemotherapy in the last 5 years | 80 (31.9) | ||
Surgery for cancer in the last 5 years | 114 (45.4) | ||
Thoracic radiation in the last 5 years | |||
Left breast | 9 (3.6) | ||
Right breast | 40 (15.9) | ||
Left lung | 16 (6.4) | ||
Right lung | 5 (2) | ||
Anthracycline exposure | 41 (16.3) | ||
Cancer in remission at the time of ablation | 205 (81.7) | ||
Recurrent cancer within a year after ablation | 11 (4.4) | ||
Multiple malignancies | 33 (13.1) | ||